CRIS Current Research Information System

PEA, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.273
NA - Nord America 11.910
EU - Europa 10.187
SA - Sud America 1.254
AF - Africa 368
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 39.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.600
SG - Singapore 4.416
IT - Italia 4.095
CN - Cina 3.771
VN - Vietnam 3.004
DE - Germania 1.456
GB - Regno Unito 1.194
HK - Hong Kong 964
IN - India 898
BR - Brasile 896
SE - Svezia 712
KR - Corea 661
FR - Francia 583
BD - Bangladesh 540
NL - Olanda 503
RU - Federazione Russa 460
JP - Giappone 345
IE - Irlanda 291
FI - Finlandia 222
AR - Argentina 139
CA - Canada 133
ID - Indonesia 124
CI - Costa d'Avorio 114
UA - Ucraina 104
ZA - Sudafrica 82
ES - Italia 81
MX - Messico 77
PH - Filippine 76
AT - Austria 75
CH - Svizzera 69
PL - Polonia 67
IQ - Iraq 63
TR - Turchia 62
EC - Ecuador 59
TH - Thailandia 53
TW - Taiwan 44
AU - Australia 43
PK - Pakistan 41
BG - Bulgaria 40
SA - Arabia Saudita 40
PA - Panama 36
CO - Colombia 35
CL - Cile 32
SC - Seychelles 31
BE - Belgio 28
HR - Croazia 25
PE - Perù 25
PT - Portogallo 25
PY - Paraguay 25
JO - Giordania 24
RO - Romania 24
GR - Grecia 22
VE - Venezuela 22
UZ - Uzbekistan 21
EE - Estonia 19
EG - Egitto 17
MA - Marocco 17
NG - Nigeria 16
TN - Tunisia 15
CZ - Repubblica Ceca 14
IL - Israele 14
MY - Malesia 14
IR - Iran 13
KE - Kenya 12
LT - Lituania 12
TG - Togo 12
AE - Emirati Arabi Uniti 11
CR - Costa Rica 11
UY - Uruguay 11
HU - Ungheria 10
NP - Nepal 10
SK - Slovacchia (Repubblica Slovacca) 10
AZ - Azerbaigian 9
DO - Repubblica Dominicana 9
JM - Giamaica 9
DZ - Algeria 8
LV - Lettonia 7
OM - Oman 7
BO - Bolivia 6
CY - Cipro 6
ET - Etiopia 6
LB - Libano 6
RS - Serbia 6
UG - Uganda 6
GA - Gabon 5
HN - Honduras 5
MD - Moldavia 5
NI - Nicaragua 5
DK - Danimarca 4
KG - Kirghizistan 4
MN - Mongolia 4
NO - Norvegia 4
QA - Qatar 4
TT - Trinidad e Tobago 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BY - Bielorussia 3
CM - Camerun 3
FJ - Figi 3
Totale 38.957
Salva come PNG Salva come JPEG
Città #
Singapore 3.032
Hefei 1.298
San Jose 1.251
Ashburn 1.236
Southend 952
Hong Kong 915
Fairfield 814
Ho Chi Minh City 738
Seoul 621
Santa Clara 618
Dallas 609
Hanoi 550
Bologna 532
Princeton 477
Boardman 433
Woodbridge 411
Beijing 401
Milan 397
Lauterbourg 388
Dong Ket 354
Seattle 352
Houston 339
Cambridge 300
Tokyo 292
Wilmington 290
Rome 288
Dublin 287
Los Angeles 274
New York 249
Chandler 245
Council Bluffs 205
Ann Arbor 185
Des Moines 159
Buffalo 150
Redondo Beach 135
Bengaluru 132
Helsinki 125
Da Nang 117
Abidjan 113
Chicago 111
Redwood City 105
Haiphong 96
Naples 95
São Paulo 91
Shanghai 86
Turin 80
Florence 79
Frankfurt am Main 76
Jakarta 70
Lappeenranta 66
San Diego 63
Berlin 62
Genoa 62
Nuremberg 56
The Dalles 56
Guangzhou 55
London 54
Amsterdam 52
Nanjing 52
Munich 51
Redmond 51
Castel Maggiore 48
Verona 47
Hangzhou 44
Phoenix 44
Tongling 44
Bremen 43
Jinan 42
Vienna 42
Medford 41
Modena 41
Toronto 40
Mumbai 38
Bari 37
Paris 37
San Francisco 37
Warsaw 37
Bern 35
Sofia 35
Hải Dương 34
Biên Hòa 33
Can Tho 32
Mexico City 32
Orem 32
Baghdad 31
Istanbul 31
Montreal 31
Padova 30
Denver 28
Falkenstein 28
Palermo 28
Saint Petersburg 28
Trieste 28
Turku 28
Atlanta 27
Johannesburg 27
Padua 27
Salt Lake City 27
Vicenza 27
Xi'an 27
Totale 23.181
Salva come PNG Salva come JPEG
Nome #
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: One stone for two birds? 1.180
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence 370
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 317
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients 315
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis 263
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel 263
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 248
Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia 245
Is it Time to Move From Intermittent to Continuous Infusion Administration of Vancomycin? 228
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 226
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 224
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics 221
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach 218
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams 214
[PK/PD profile and post-marketing surveillance of levofloxacin] 212
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 209
Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales 208
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use 202
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 202
Enhancement of in-vitro activity of ofloxacin and gentamicin by rat serum 202
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections 201
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections 201
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 192
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 190
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction 190
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 189
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 187
Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data 186
Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study 185
Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis 183
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow 182
Methicillin-resistant Staphylococcus epidermidis knee prosthetic infection treatment with two-stage revision and fosfomycin–rifampin combination therapy: a case report 182
Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales 181
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 179
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 178
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 177
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 176
Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections 175
A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue 173
Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections? 173
Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis 172
Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. 172
Acute wound infections management: the ‘Don’ts’ from a multidisciplinary expert panel 172
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 172
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 171
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 169
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 168
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run 168
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis 166
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions 166
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 165
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections 164
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. 164
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid 161
Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections 161
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae 160
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. 158
Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis 156
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 156
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 156
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: A strategy useful for raising the bar? 154
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 153
Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice 151
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring 151
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# 150
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol 150
Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia? 149
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 148
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 148
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem 147
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 146
Blood concentrations and clinical effect of cyclosporin in psoriasis 146
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients 146
Population Pharmacokinetic and Pharmacodynamic Analysis for Maximizing the Effectiveness of Ceftobiprole in the Treatment of Severe Methicillin-Resistant Staphylococcal Infections 145
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? 145
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings 144
The current role of glycopeptides in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts 143
A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 143
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections 142
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 142
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM) 141
Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia 141
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 141
Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia 139
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections 139
Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis 138
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors 138
Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT 138
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients 137
Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action 135
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections 135
β-blockers and diltiazem combination—bear in mind the risk of heart block 135
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6 133
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of bsis, cutis, and ciais caused by enterobacterales in critically ill adult patients 133
Population Pharmacokinetics of a Novel Oral Fosfomycin Prophylactic Scheme in the Plasma and Prostate of Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia 132
Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients 131
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring 131
Liposome encapsulated daunorubicin (daunoxome) for acute leukemia 131
Two Comprehensive Liquid Chromatography High-Resolution Mass Spectrometry (UPLC-MS/MS) Multi-Methods for Real-Time Therapeutic Drug Monitoring (TDM) of Five Novel Beta-Lactams and of Fosfomycin Administered by Continuous Infusion 130
Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis 130
Totale 18.395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021775 0 0 0 0 0 0 0 0 0 0 0 775
2021/20223.502 126 51 221 215 623 321 112 289 327 163 460 594
2022/20232.836 354 309 161 431 155 184 173 157 489 92 180 151
2023/20242.003 99 171 129 207 178 204 204 180 135 207 160 129
2024/20257.972 275 1.026 744 590 991 404 690 246 170 756 655 1.425
2025/202619.256 1.339 2.328 2.140 1.682 1.373 843 2.207 994 3.020 1.277 1.201 852
Totale 39.940